Umeå University's logo

Change search
Link to record
Permanent link

Direct link
Esteva-Socias, MargalidaORCID iD
Publications (3 of 3) Show all publications
Esteva-Socias, M. & Aguilo, F. (2024). METTL3 as a master regulator of translation in cancer: mechanisms and implications. NAR Cancer, 6(1), Article ID zcae009.
Open this publication in new window or tab >>METTL3 as a master regulator of translation in cancer: mechanisms and implications
2024 (English)In: NAR Cancer, E-ISSN 2632-8674, Vol. 6, no 1, article id zcae009Article in journal (Refereed) Published
Abstract [en]

Translational regulation is an important step in the control of gene expression. In cancer cells, the orchestration of both global control of protein synthesis and selective translation of specific mRNAs promote tumor cell survival, angiogenesis, transformation, invasion and metastasis. N6-methyladenosine (m6A), the most prevalent mRNA modification in higher eukaryotes, impacts protein translation. Over the past decade, the development of m6A mapping tools has facilitated comprehensive functional investigations, revealing the involvement of this chemical mark, together with its writer METTL3, in promoting the translation of both oncogenes and tumor suppressor transcripts, with the impact being context-dependent. This review aims to consolidate our current understanding of how m6A and METTL3 shape translation regulation in the realm of cancer biology. In addition, it delves into the role of cytoplasmic METTL3 in protein synthesis, operating independently of its catalytic activity. Ultimately, our goal is to provide critical insights into the interplay between m6A, METTL3 and translational regulation in cancer, offering a deeper comprehension of the mechanisms sustaining tumorigenesis.

Place, publisher, year, edition, pages
Oxford University Press, 2024
National Category
Biochemistry and Molecular Biology Cancer and Oncology
urn:nbn:se:umu:diva-222414 (URN)10.1093/narcan/zcae009 (DOI)38444581 (PubMedID)2-s2.0-85187108906 (Scopus ID)
EU, Horizon 2020, 956810Swedish Research Council, 2022-01322Swedish Cancer Society, 22 2455 Pj
Available from: 2024-03-22 Created: 2024-03-22 Last updated: 2024-03-22Bibliographically approved
Cerón-Pisa, N., Iglesias, A., Shafiek, H., Martín-Medina, A., Esteva-Socias, M., Muncunill, J., . . . Sauleda, J. (2022). Hsa-Mir-320c, Hsa-Mir-200c-3p, and Hsa-Mir-449c-5p as Potential Specific miRNA Biomarkers of COPD: A Pilot Study. Pathophysiology, 29(2), 143-157
Open this publication in new window or tab >>Hsa-Mir-320c, Hsa-Mir-200c-3p, and Hsa-Mir-449c-5p as Potential Specific miRNA Biomarkers of COPD: A Pilot Study
Show others...
2022 (English)In: Pathophysiology, ISSN 0928-4680, E-ISSN 1873-149X, Vol. 29, no 2, p. 143-157Article in journal (Refereed) Published
Abstract [en]

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease commonly induced by cigarette smoke. The expression of miRNAs can be altered in patients with COPD and could be used as a biomarker. We aimed to identify a panel of miRNAs in bron-choalveolar lavage (BAL) to differentiate COPD patients from smokers and non-smokers with normal lung function. Accordingly, forty-five subjects classified as COPD, smokers, and non-smokers (n = 15 per group) underwent clinical, functional characterization and bronchoscopy with BAL. The mean age of the studied population was 61.61 ± 12.95 years, BMI 25.72 ± 3.82 Kg/m2, FEV1/FVC 68.37 ± 12.00%, and FEV1 80.07 ± 23.63% predicted. According to microarray analysis, three miRNAs of the most upregulated were chosen: miR-320c, miR-200c-3p, and miR-449c-5p. These miRNAs were validated by qPCR and were shown to be differently expressed in COPD patients. ROC analysis showed that these three miRNAs together had an area under the curve of 0.89 in differentiating COPD from controls. Moreover, in silico analysis of candidate miRNAs by DIANA-miRPath showed potential involvement in the EGFR and Hippo pathways. These results suggest a specific 3-miRNA signature that could be potentially used as a biomarker to distinguish COPD patients from smokers and non-smoker subjects.

Place, publisher, year, edition, pages
MDPI, 2022
biomarker, COPD, lung disease, miRNAs
National Category
Respiratory Medicine and Allergy
urn:nbn:se:umu:diva-194409 (URN)10.3390/pathophysiology29020013 (DOI)2-s2.0-85128447816 (Scopus ID)
Available from: 2022-05-04 Created: 2022-05-04 Last updated: 2024-03-22Bibliographically approved
Achour, C., Bhattarai, D. P., Esteva-Socias, M., Rodriguez-Barrueco, R., Malla, S., Seier, K., . . . Aguilo, F.Reshaping the role of METTL3 in breast tumorigenesis.
Open this publication in new window or tab >>Reshaping the role of METTL3 in breast tumorigenesis
Show others...
(English)Manuscript (preprint) (Other academic)
National Category
Cell Biology Biochemistry and Molecular Biology
urn:nbn:se:umu:diva-201048 (URN)
Available from: 2022-11-16 Created: 2022-11-16 Last updated: 2024-03-22

Search in DiVA

Show all publications